Session 2: GIST

Moderator(s)

• 

  Lori Rink, PhD (she/her/hers)

  Associate Professor
  Fox Chase Cancer Center
  Philadelphia, Pennsylvania, United States
• 

  Patrick Schöffski, Prof Dr

  Head of Department General Medical Oncology
  Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven
  Leuven, Vlaams-Brabant, Belgium

Presentations:

• 10:30 AM – 11:30 AM PST

  THE NOVEL KIT INHIBITOR IDRX-42 SHOWS PROMISING ACTIVITY IN 2ND AND LATER-LINE GASTROINTESTINAL STROMAL TUMORS: RESULTS FROM A PHASE 1 STUDY (STRATEGIST 1)
  

  Author: Suzanne George, MD (she/her/hers) – Dana-Farber Cancer Institute

  Co-Author: Michael C. Heinrich, MD – Portland VA Health Care System and OHSU Knight Cancer Institute

  Co-Author: Jonathan Trent, MD, PhD – Sylvester Comprehensive Cancer Center, University of Miami Health System

  Co-Author: César Serrano, MD, PhD – Vall d’Hebron Institute of Oncology

  Co-Author: Sebastian Bauer, MD (he/him/his) – Sarcoma Center, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, and German Cancer Consortium (DKTK), Partner Site University Hospital Essen

  Co-Author: Margaret von Mehren, MD – Fox Chase Cancer Center

  Co-Author: Neeta Somaiah, MD – The University of Texas MD Anderson Cancer Center

  Co-Author: Peter Reichardt, MD, PhD – Helios Klinikum Berlin-Buch

  Co-Author: George Demetri, MD – Dana-Farber Cancer Institute – Sarcoma Center; IDRx

  Co-Author: Nick Lydon, PhD – IDRx

  Co-Author: David Kerstein, MD – IDRx

  Co-Author: Jaap Verweij, MD, PhD – IDRx

  Co-Author: Vivek Kadambi, PhD – IDRx

  Co-Author: Jessica Christo, n/a – IDRx

  Co-Author: Sean Kim, PhD – IDRx

  Co-Author: Debbie Johnson, BS – IDRx

  Co-Author: James Shao, MS – IDRx

  Co-Author: Patrick Schöffski, Prof Dr – Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven
• 10:30 AM – 11:30 AM PST

  A PHASE II, SINGLE ARM STUDY OF AVELUMAB IN COMBINATION WITH AXITINIB IN PATIENTS WITH UNRESECTABLE/METASTATIC GASTROINTESTINAL STROMAL TUMOR AFTER FAILURE OF STANDARD THERAPY (AXAGIST)
  

  Author: Katarzyna Kozak, MD PhD – Maria Sklodowska-Curie National Research Institute of Oncology

  Co-Author: Anna Klimczak, MD – Maria Sklodowska-Curie National Research Institute of Oncology

  Co-Author: Pawel Teterycz, MD, PhD – Maria Sklodowska-Curie National Research Institute of Oncology

  Co-Author: Tomasz Switaj, MD PhD – Maria Sklodowska-Curie National Research Institute of Oncology

  Co-Author: Pawel Rogala, MD PhD – Maria Sklodowska-Curie National Research Institute of Oncology

  Co-Author: Maria Abbondanza Pantaleo, MD – Università di Bologna

  Co-Author: Piotr Ł. Rutkowski, Professor, MD, PhD – Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw Poland
• 10:30 AM – 11:30 AM PST

  FIRST-IN-HUMAN PERSONALIZED, N-OF-1 COMBINATION THERAPIES FOR ADVANCED GASTROINTESTINAL STROMAL TUMORS
  

  Author: Sangkyu Noh, DO – University of Arizona - Tucson

  Co-Author: Ashwyn Sharma, MD – University of California, San Diego

  Co-Author: Shumei Kato, MD – University of California, San Diego

  Co-Author: Paul Fanta, M.D. – University of California, San Diego

  Co-Author: Razelle Kurzrock, M.D., F.A.C.P. – Medical College of Wisconsin

  Co-Author: Jason K. Sicklick, M.D., FACS – University of California, San Diego
• 10:30 AM – 11:30 AM PST

  MENIN INHIBITOR ZIFTOMENIB SYNERGIZES WITH IMATINIB IN TYROSINE KINASE INHIBITOR (TKI)-RESISTANT GASTROINTESTINAL STROMAL TUMOR MODELS
  

  Author: Asako McCloskey, PhD – Kura Oncology, Inc

  Co-Author: Quinn Reilly, B.S. – University of Utah

  Co-Author: Judy Wu, B.S. – Kura Oncology, Inc

  Co-Author: Francis Burrows, PhD – Kura Oncology, Inc
• 10:30 AM – 11:30 AM PST

  SELECTIVE INTERNAL RADIATION THERAPY FOR SUCCINATE DEHYDROGENASE DEFICIENT GASTROINTESTINAL STROMAL TUMORS DEMONSTRATES ENCOURAGING DURABLE RESPONSE RATES: AN INTERNATIONAL MULTICENTER CASE SERIES
  

  Author: Zachary T. Berman, MD – Univeristy of California, San Diego

  Co-Author: Peter Hohenberger, MD – Mannheim University

  Co-Author: Steven C. Rose, MD – University of California, San Diego

  Co-Author: Ramesh Bulusu, MD – Cambridge University

  Co-Author: Paul Fanta, M.D. – University of California, San Diego

  Co-Author: Jason K. Sicklick, M.D., FACS – University of California, San Diego
• 10:30 AM – 11:30 AM PST

  NOVEL MODELS FOR THE FUNCTIONAL CHARACTERIZATION OF SDHA GERMLINE VARIANTS TO PREDICT CANCER RISK
  

  Author: Michael C. Heinrich, MD – Portland VA Health Care System and OHSU Knight Cancer Institute

  Co-Author: Jason Kent, Ph.D. – OHSU Knight Cancer Institute